

Rolf Lewensohn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7153313/publications.pdf>

Version: 2024-02-01

58
papers

1,515
citations

471061

17
h-index

329751

37
g-index

61
all docs

61
docs citations

61
times ranked

2215
citing authors

#	ARTICLE	IF	CITATIONS
1	Human papillomavirus (HPV) DNA in tonsillar cancer: Clinical correlates, risk of relapse, and survival. <i>International Journal of Cancer</i> , 2000, 89, 300-304.	2.3	356
2	SPACE – A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. <i>Radiotherapy and Oncology</i> , 2016, 121, 1-8.	0.3	270
3	Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. <i>Radiation Oncology</i> , 2017, 12, 206.	1.2	92
4	The HILUS-Trial – a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1200-1210.	0.5	92
5	Defective caspase-3 relocalization in non-small cell lung carcinoma. <i>Oncogene</i> , 2001, 20, 2877-2888.	2.6	69
6	Label-Free Surface Protein Profiling of Extracellular Vesicles by an Electrokinetic Sensor. <i>ACS Sensors</i> , 2019, 4, 1399-1408.	4.0	54
7	Exosomal RNA-profiling of pleural effusions identifies adenocarcinoma patients through elevated miR-200 and LCN2 expression. <i>Lung Cancer</i> , 2018, 124, 45-52.	0.9	53
8	Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. <i>Clinical Proteomics</i> , 2015, 12, 8.	1.1	31
9	Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer. <i>Molecular Oncology</i> , 2019, 13, 376-391.	2.1	28
10	First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies. <i>Investigational New Drugs</i> , 2015, 33, 1232-1241.	1.2	27
11	Radiation-induced brachial plexus toxicity after SBRT of apically located lung lesions. <i>Acta Oncologica</i> , 2019, 58, 1178-1186.	0.8	24
12	DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines. <i>BMC Cancer</i> , 2015, 15, 628.	1.1	23
13	Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 60332-60347.	0.8	20
14	Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. <i>Clinical Cancer Research</i> , 2016, 22, 366-373.	3.2	20
15	Compounds from the marine sponge <i>Cribrochalina vasculum</i> offer a way to target IGF-1R mediated signaling in tumor cells. <i>Oncotarget</i> , 2016, 7, 50258-50276.	0.8	20
16	A Swedish Study of Chemoradiation in Squamous Cell Carcinoma of the Esophagus. <i>Acta Oncologica</i> , 2001, 40, 566-573.	0.8	19
17	miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. <i>Biochemical and Biophysical Research Communications</i> , 2019, 511, 260-265.	1.0	19
18	Treatment patterns and survival outcomes for small-cell lung cancer patients – a Swedish single center cohort study. <i>Acta Oncologica</i> , 2020, 59, 388-394.	0.8	18

#	ARTICLE	IF	CITATIONS
19	The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy. <i>PLoS ONE</i> , 2020, 15, e0240973.	1.1	18
20	Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden. <i>Lung Cancer</i> , 2018, 120, 75-81.	0.9	17
21	A fine-needle aspiration-based protein signature discriminates benign from malignant breast lesions. <i>Molecular Oncology</i> , 2018, 12, 1415-1428.	2.1	15
22	Detection of Tumor-Associated Membrane Receptors on Extracellular Vesicles from Non-Small Cell Lung Cancer Patients via Immuno-PCR. <i>Cancers</i> , 2021, 13, 922.	1.7	15
23	An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2020, 132, 24-34.	1.3	14
24	Cell cycle arrest and DNA damage after melphalan treatment of the human myeloma cell line RPMI 8226. <i>European Journal of Haematology</i> , 1991, 47, 161-167.	1.1	13
25	Marine Sponge <i>Cribrochalina vasculum</i> Compounds Activate Intrinsic Apoptotic Signaling and Inhibit Growth Factor Signaling Cascades in Non-small Cell Lung Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2941-2954.	1.9	13
26	Preclinical activity of melflufen (J1) in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 59322-59335.	0.8	13
27	Combined Treatment Modalities in Esophageal Cancer: Should chemotherapy be included?. <i>Acta Oncologica</i> , 1994, 33, 439-450.	0.8	12
28	Exploiting Electrostatic Interaction for Highly Sensitive Detection of Tumor-Derived Extracellular Vesicles by an Electrokinetic Sensor. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 42513-42521.	4.0	12
29	Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma. <i>Molecular Oncology</i> , 2016, 10, 719-734.	2.1	10
30	Multiplexed electrokinetic sensor for detection and therapy monitoring of extracellular vesicles from liquid biopsies of non-small-cell lung cancer patients. <i>Biosensors and Bioelectronics</i> , 2021, 193, 113568.	5.3	10
31	Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment. <i>Oncogene</i> , 2002, 21, 65-77.	2.6	10
32	Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1215-1224.	0.8	9
33	Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients. <i>Npj Systems Biology and Applications</i> , 2020, 6, 25.	1.4	9
34	Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer. <i>Acta Oncologica</i> , 2018, 57, 231-238.	0.8	9
35	Educational level, management and outcomes in small-cell lung cancer (SCLC): A population-based cohort study. <i>Lung Cancer</i> , 2020, 139, 111-117.	0.9	8
36	EPHA2 Interacts with DNA-PKcs in Cell Nucleus and Controls Ionizing Radiation Responses in Non-Small Cell Lung Cancer Cells. <i>Cancers</i> , 2021, 13, 1010.	1.7	8

#	ARTICLE	IF	CITATIONS
37	Multiplex immune protein profiling of fine-needle aspirates from patients with non-small-cell lung cancer reveals signatures associated with PD-L1 expression and tumor stage. <i>Molecular Oncology</i> , 2021, 15, 2941-2957.	2.1	8
38	Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia. <i>Pharmacogenomics Journal</i> , 2020, 20, 179-191.	0.9	7
39	Comparison and optimization of nanoscale extracellular vesicle imaging by scanning electron microscopy for accurate size-based profiling and morphological analysis. <i>Nanoscale Advances</i> , 2021, 3, 3053-3063.	2.2	7
40	Analysis of Chromatin Opening in Heterochromatic Non-Small Cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 174-187.	0.4	6
41	Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing. <i>Lung Cancer</i> , 2020, 147, 106-114.	0.9	5
42	Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. <i>Cancers</i> , 2021, 13, 4164.	1.7	5
43	Analysis of human papillomaviruses and human polyomaviruses in lung cancer from Swedish never-smokers. <i>Acta Oncologica</i> , 2020, 59, 28-32.	0.8	4
44	Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome. <i>Molecular Oncology</i> , 2022, 16, 3620-3641.	2.1	4
45	Toward Rare Blood Cell Preservation for RNA Sequencing. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 352-359.	1.2	3
46	ALK-Brain Prognostic Index—Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases. <i>Cancers</i> , 2020, 12, 1804.	1.7	3
47	Efficacy of peptide bound m-l-sarcosylsin (peptichemio) on melphalan resistant human myeloma cells in vitro. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1991, 8, 265-269.	1.0	3
48	Cytotoxic Alkylolins of the Sponge <i>Cribrochalina vasculum</i> : Structure, Synthetic Analogs and SAR Studies. <i>Marine Drugs</i> , 2022, 20, 265.	2.2	3
49	Extending hypofractionated stereotactic body radiotherapy to tumours larger than 70cc—effects and side effects. <i>Acta Oncologica</i> , 2021, 60, 305-311.	0.8	2
50	Interphase cell death as related to the cell cycle of melphalan-treated human myeloma cells. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1991, 8, 63-67.	1.0	1
51	The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, , .	1.2	1
52	Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial. <i>Acta Oncologica</i> , 2022, 61, 869-873.	0.8	1
53	In Response to Rosenberg et al. “The Nordic-HILUS Trial: Ultracentral Lung SABR and a Narrow Therapeutic Window”, <i>Journal of Thoracic Oncology</i> , 2021, 16, e81-e82.	0.5	0
54	Analysis of γ H2AX and NHEJ Signaling as Molecular Determinants for GOSensitivity in AML. <i>Blood</i> , 2008, 112, 4854-4854.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1. Blood, 2010, 116, 1838-1838.	0.6	0
56	Individualized Multidrug Resistance In Acute Myeloid Leukemia. Blood, 2010, 116, 2491-2491.	0.6	0
57	Educational level and outcome in small-cell lung cancer (SCLC): A population-based study.. Journal of Clinical Oncology, 2016, 34, e20096-e20096.	0.8	0
58	Clinical significance of the tumor expression of PD-L1 in lung cancer.. Journal of Clinical Oncology, 2016, 34, e20031-e20031.	0.8	0